Results 211 to 220 of about 20,467 (239)

Faricimab for treating diabetic macular oedema [PDF]

, 2021
To appraise the clinical and cost effectiveness of faricimab within its marketing authorisation for treating diabetic macular oedema.
Frampton, Geoff, Kalita, Neelam, Pickett, Karen, Maund, Emma, Takahashi, Marcia Tomie, Scott, David Alexander, Cooper, Keith   +6 more
openaire  

Some of the next articles are maybe not open access.

Related searches:

[Treatment of diabetic macular oedema].

Vnitrni lekarstvi, 2013
Diabetic macular oedema (DMO) is currently the main complication associated with diabetes. The percentage of patients with DMO grows alongside the increasing number of diabetes occurrences. The DMO treatment has seen major developments in the past few years.
openaire   +1 more source

Ranibizumab

Drugs, 2012
Ranibizumab, an intravitreally administered inhibitor of vascular endothelial growth factor (VEGF), is approved for the treatment of visual impairment associated with diabetic macular oedema (DME) in the EU. In four well designed, phase II or III trials (RESOLVE, RESTORE, RIDE and RISE), 1-2 years' treatment with ranibizumab was more effective than ...
openaire   +2 more sources

Effect of Therapy on Diabetic Macular Oedema

2016
Anti-vascular endothelial growth factor (VEGF) therapies have changed the dynamics in the management of patients with diabetic macular oedema (DME); increasingly it is the treatment of choice when there is extensive oedema in foveal-involving DME. The role of laser in the anti-VEGF era has to be re-examined. Despite the efficacy of laser, the mechanism
Samia Fatum, Elizabeth Pearce, Victor Chong   +2 more
openaire   +1 more source

[Therapeutic possibilities for diabetic macular oedema].

Nederlands tijdschrift voor geneeskunde, 2006
The number of patients with diabetes mellitus will increase over the coming years, so that there will also be more patients with diabetic macular oedema. Diabetic macular oedema and diabetic retinopathy are the most important causes of legal blindness in adults.
N G M, Wiemer, B C P, Polak, M A H, Veckeneer   +2 more
openaire   +1 more source

Cystoid Macular Oedema in Diabetic Retinopathy

1976
In cases of cystoid macular oedema fluorescein angiographic leakage points within the perimacular capillary bed will reveal the origin of serum spreading toward the macula. Diabetic retinopathy being associated with this type of vascular changes will not be amendable to any mode of medical therapy.
H. Freyler, I. Egerer
openaire   +1 more source

Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema

Drugs, 2010
Diabetic retinopathy (DR) is a major cause of blindness in Europe and North America, and the incidence is expected to increase in parallel with the rising incidence of diabetes mellitus. This article reviews the current state of knowledge of the epidemiology, clinical presentation and pathophysiology of DR and its principal associated complications ...
openaire   +3 more sources

The diagnostic value of systemic immune-inflammation index in diabetic macular oedema

Australasian journal of optometry, The, 2022
Bengi Ece Kurtul, Sait Coskun Ozcan, Deniz Ozarslan Ozcan   +2 more
exaly  

[Surgical treatment of diabetic macular oedema].

Klinische Monatsblatter fur Augenheilkunde, 2010
The therapy for diabetic macular oedema often remains unsatisfactory for both patient and treating physician. Therapeutic approaches comprise laser therapy as the evidence-based "basic therapy" and increasingly also intravitreal injections of drugs which, however, have only a limited effect.
M A, Gamulescu, W A, Herrmann, H, Helbig
openaire   +1 more source

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Lancet, The, 2022
Francis Abreu, Zdenka Haskova, Anat Loewenstein   +2 more
exaly